Developing game changing treatments and cell therapies for severe diseases
We develop and commercialize innovative treatments for patients with severe and life-threatening conditions. Our drug canditates have the potential to improve outcomes in the treatment of neurological and ophthalmic disease and for ground-breaking regenerative cell therapies. They give hope for patients lacking satisfactory alternatives.
“We are very excited about the clinical potential for ILB, which may prove to be a game changing treatment for many devastating diseases.”Professor Ann LoganScientific Director, Neuregenix Ltd.